Device Trial Radar · NCT02748408
The Medacta International SMS Post-Marketing Surveillance Study
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
Jul 2015
Primary completion
Jul 2032
Study completion Jul 2032
Sponsor
- Lead sponsor
- Medacta International SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 22, 2016
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Post-Marketing Surveillance of SMS femoral stem prosthesis.
Conditions
- Arthrosis
- Traumatic Arthritis
- Rheumatoid Polyarthritis
- Congenital Hip Dysplasia
- Avascular Necrosis of the Femoral Head
Interventions
SMS femoral stemDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- survivorship of the Medacta SMS femoral stemTime frame: 10-year
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Herz-Jesu Krankenhaus
Vienna, Austria · Recruiting
Istituto Ortopedico Galezzi
Milan, Milan, Italy · Recruiting
Bürgerspital Solothurn
Solothurn, Switzerland · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.